Related Experiment Videos
[Antiretroviral therapy 2003. The current status]
1Medizinische Klinik, Klinikum Salzgitter.
MMW Fortschritte Der Medizin
|March 12, 2004
Summary
New HIV treatments in 2003 include entry inhibitors like enfurvitide, expanding beyond nucleoside reverse transcriptase inhibitors (NRTI) and protease inhibitors (PI). Promising vaccination studies emerge, while immunomodulatory approaches show limited success.
Area of Science:
- Infectious Diseases
- Pharmacology
- Immunology
Background:
- Antiretroviral therapy for HIV infection is evolving beyond nucleoside and nucleotide reverse transcriptase inhibitors (NRTI, NNRTI, NtRTI) and protease inhibitors (PI).
- The landscape of HIV treatment is expanding with the anticipated approval of entry inhibitors (EI), exemplified by enfurvitide (T20).
- Initial long-term data for tenofovir, available since early 2002, are emerging.
Purpose of the Study:
- To review the advancements and upcoming changes in antiretroviral treatment strategies for HIV infection.
- To highlight new drug classes and candidates in clinical development.
- To assess the progress of immunomodulatory and vaccination approaches in HIV management.
Main Methods:
- Review of current and pipeline antiretroviral medications.
- Analysis of emerging clinical data for HIV therapeutics.
- Evaluation of studies on immunomodulation and vaccination for HIV.
Main Results:
- Entry inhibitors (EI) like enfurvitide (T20) are set to expand treatment options.
- New NRTIs (emtricitabine - FTC) and PIs (amdoxovir, Atazanavir) are in development.
- Immunomodulatory strategies have yielded disappointing results, whereas vaccination studies show promise.
Conclusions:
- The antiretroviral treatment paradigm for HIV is broadening with new drug classes and agents.
- Vaccination research presents a potentially fruitful avenue for HIV intervention.
- Updated treatment recommendations reflect the dynamic nature of HIV therapy.